netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online
Formulary
Red

Film coated tablets: 20mg, 30mg, 40mg, 50mg

 
Link  NICE TA 310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
View adult BNF View SPC online
Formulary
Red
NHS England
150mg capsules 
Link  NICE TA 536: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Brigatinib (Alunbrig®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE 
  • Link  NICE TA 570: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
    Link  NICE TA 670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
       
    Cytotoxic Drug Cabozantinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy 
  • Link  NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 200mg, 250mg

     
    Link  NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dacomitinib (Vizimpro®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England

    Dacomitinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides it according to the commercial arrangement.

     
    Link  NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Cytotoxic Drug Dasatinib
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 20mg, 50mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Everolimus (Votubia®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 2.5mg, 5mg, 10mg


    -Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
    -a
    pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


    Tablets: 5mg and 10mg


    - Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    - Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
    - Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    -Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


     

     
    Link  NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
    Link  NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Gefitinib (Iressa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 250mg

     
    Link  NICE TA 192: Lung cancer (non-small-cell, first line) - gefitinib
    Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    Cytotoxic Drug Imatinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 100mg & 400mg

     
    Link  NICE TA 70: Leukaemia (chronic myeloid) - imatinib
    Link  NICE TA 86: Gastro-intestinal stromal tumours (GIST) - imatinib
    Link  NICE TA 209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
    Link  NICE TA 326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Larotrectinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    Cancer Drugs Fund

    Oral solution: 20mg/mL

    Recommended for use according to NICE criteria (TA630)

     
    Link  NICE TA 630: Larotrectinib for treating NTRK fusion-positive solid tumours
       
    Lorlatinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    NHS England

    Tablets: 25mg, 100mg

     

    Recommended for use according to NICE criteria (TA628)

     
    Link  NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
       
    Nilotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 150mg, 200mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Nintedanib (Vargatef®)
    View adult BNF View SPC online
    Formulary
    Red

    Soft capsules: 100mg, 150mg

     
    Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
    Link  NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
       
    Pazopanib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 200mg, 400mg

     
    Link  NICE TA 215: Renal cell carcinoma (first line metastatic) - pazopanib
       
    Regorafenib (Stivarga® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 40mg

     
    Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
    Link  NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
       
    Sorafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 200mg

     
    Link  NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sunitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 50mg 100mg, 400mg

     
    Link  NICE TA 169: Renal cell carcinoma - sunitinib
    Link  NICE TA 178: Renal cell carcinoma
    Link  NICE TA 179: Gastrointestinal stromal tumours - sunitinib
       
    Trifluridine and tipiracil
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

     
    Link  NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
       
    Vemurafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 240mg

     
    Link  NICE TA 269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
    Link  NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Venetoclax (Venclyxto®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablets: 10 mg, 50 mg & 100 mg

     
    Link  NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
    Link  NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
       
    08.01.05  Expand sub section  Taxanes
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    08.01.05  Expand sub section  Trabectedin
    08.01.05  Expand sub section  Trastuzumab to top
    08.01.05  Expand sub section  Tretinoin
    08.01.05  Expand sub section  Vismodegib
     ....
     Non Formulary Items
    Cytotoxic Drug  Vandetanib  (Caprelsa®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary